Chronic Diseases and Translational Medicine最新文献

{"title":"Amyloid-Related Imaging Abnormality (ARIA) Beyond the APOE-ε4 Allele","authors":"Valentinus Besin,&nbsp;Farizky Martriano Humardani,&nbsp;Fenny Lanawati Yudiarto,&nbsp;Paulus Anam Ong,&nbsp;Sulistyo Emantoko Dwi Putra,&nbsp;Ratih Asmana Ningrum","doi":"10.1002/cdt3.70006","DOIUrl":"https://doi.org/10.1002/cdt3.70006","url":null,"abstract":"<p>Monoclonal antibodies (mAbs) have made significant progress in the treatment of Alzheimer's disease (AD). However, mAbs are associated with adverse effects, including Amyloid-Related Imaging Abnormality (ARIA), which manifests as edema or effusion (ARIA-E) and hemorrhage (ARIA-H). The mechanisms behind these effects are not yet fully understood. Moreover, spontaneous ARIA has been insufficiently explored, and mAb therapies, particularly lecanemab, have mainly focused on patients with the <i>APOE-ε4</i> allele carrier. This review aims to address this gap by examining the mechanisms of spontaneous ARIA, ARIA induced by mAbs, and the influence of genetic variants on ARIA development. The autoantibody-Aβ-mediated immune response targets excessive Aβ deposits, increasing immune activity through microglial reactivity. The heightened immune response, driven by Aβ accumulation in blood vessels, promotes angiopathy and inflammation, potentially contributing to spontaneous ARIA. The <i>APOE-ε4</i> allele carrier is more strongly associated with ARIA-E because it redistributes Aβ deposition from the brain to blood vessels, influencing microglial reactivity. The redistribution enhances vascular integrity and reduces the risk of ARIA-H. However, it also increases the likelihood of ARIA-E due to Aβ accumulation in the vasculature, triggering inflammation. In contrast, the development of ARIA-H is linked to increased <i>TREM2</i> expression and microglial reactivity, leading to impaired vascular integrity and disrupted matrix remodeling, which worsens the condition. Additionally, the adverse effects of mAbs may extend beyond the <i>APOE-ε4</i> allele, possibly impacting other genetic variants involved in microglial reactivity, Aβ redistribution, and vascular integrity.</p>","PeriodicalId":32096,"journal":{"name":"Chronic Diseases and Translational Medicine","volume":"11 3","pages":"186-196"},"PeriodicalIF":0.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cdt3.70006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluation of NaTto Red Yeast Rice on Regulating Blood Lipid (ENTRY) Study: A Multicenter, Double-Placebo, Double-Blinded, Randomized Controlled Trial in Chinese Adults","authors":"Shufeng Chen,&nbsp;Fangchao Liu,&nbsp;Jinyue Li,&nbsp;Fengchao Liang,&nbsp;Jianxin Li,&nbsp;Jie Cao,&nbsp;Donghua Liu,&nbsp;Keyong Huang,&nbsp;Hongfan Li,&nbsp;Xiangfeng Lu,&nbsp;Jianfeng Huang,&nbsp;Dongfeng Gu","doi":"10.1002/cdt3.70005","DOIUrl":"https://doi.org/10.1002/cdt3.70005","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Statins are the first line of treatment for dyslipidemia, but their side effects often reduce medication compliance. Natto and red yeast rice are natural ingredients with lipid-lowering effects. However, the efficacy of Natto Red Yeast Rice (NRYR) supplement in combination with statins in regulating blood lipid levels has not been fully evaluated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A multicenter, double-blinded, randomized-controlled trial was conducted among individuals with low-density lipoprotein cholesterol (LDL-C) of 3.4 to 5.0 mmol/L at six sites in China, of those at moderate risk of cardiovascular disease (CVD) are prioritized. Participants are enrolled and randomly assigned into four groups by a combination of NRYR (or its placebo) and Simvastatin (or its placebo) in a ratio of 1:1:1:1. After examination at baseline, all participants underwent intervention for 3 months and two follow-up visits at 1 month and 3 months after the intervention. The primary outcome is the change in LDL-C level at 3 months, and secondary outcomes include changes in levels of other lipid profiles and biomarkers, as well as calculated 10-year CVD risk. A total of 1136 participants were randomly assigned, of whom 1110 received the intervention.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Discussion</h3>\u0000 \u0000 <p>This study may provide new evidence for the efficacy of NRYR supplement in combination with statins to regulate lipid levels and optimize lipid management.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Trial Registration</h3>\u0000 \u0000 <p>Chinese Clinical Trial Registry database: registration nos. ChiCTR2200064214, ChiCTR2200064215.</p>\u0000 </section>\u0000 </div>","PeriodicalId":32096,"journal":{"name":"Chronic Diseases and Translational Medicine","volume":"11 2","pages":"122-129"},"PeriodicalIF":0.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cdt3.70005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144219974","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contemporary Perspectives on Chronic Renal Disorders","authors":"Deenadhayalan Ashok,&nbsp;Poornima Ajay Manjrekar,&nbsp;Bhushan C. Shetty,&nbsp;Sujina S. S,&nbsp;Rukmini Mysore Srikantiah,&nbsp;Sowndarya Kollampare","doi":"10.1002/cdt3.70004","DOIUrl":"https://doi.org/10.1002/cdt3.70004","url":null,"abstract":"<p>The prevalence of renal diseases and its associated burden on healthcare have tremendously risen in the past few years. From simple markers assessing kidney function, current renal research delves into understanding the diseases at the cellular and molecular levels and not just at treating, but at improving quality of life, arresting progression and providing personalized diagnostics and therapy. This narrative review highlights the improvements in diagnostic applications of kidney disease and briefly discusses a few notable biomarkers emphasizing the high throughput omics technologies, as well as contemporary perspectives on renal research. A thorough literature search was performed on PubMed, Scopus, Web of Science, and Medline. Suitable Mesh terms were included for the search strategy, and relevant evidence was documented. Language models and pharmacognosy, along with other omics strategies, impose a better understanding of the renal disease, and the remarkable discoveries of noninvasive biomarkers, urine 273-peptide classifier, and urine peptides-based fibrosis classifier have unraveled the associations between mechanistic studies and novel therapeutic drugs. Strides in biomarker research have been able to delineate stages and types with superior specificity and sensitivity, thereby providing a better diagnosis. Renal research reflects a powerful, dynamic, and multifaceted field that drives better advancements and discoveries in personalized medicine, drug interventions, and patient-centered outcomes. Understanding the tangled relationship of the etiology of kidney disease, these developments and future research hold promise for individuals affected by kidney diseases</p>","PeriodicalId":32096,"journal":{"name":"Chronic Diseases and Translational Medicine","volume":"11 2","pages":"89-104"},"PeriodicalIF":0.0,"publicationDate":"2025-04-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cdt3.70004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144220239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Performance of Computer-Aided Detection Software in Tuberculosis Case Finding in Township Health Centers in China","authors":"Xuefang Cao,&nbsp;Boxuan Feng,&nbsp;Bin Zhang,&nbsp;Dakuan Wang,&nbsp;Jiang Du,&nbsp;Yijun He,&nbsp;Tonglei Guo,&nbsp;Shouguo Pan,&nbsp;Zisen Liu,&nbsp;Jiaoxia Yan,&nbsp;Qi Jin,&nbsp;Lei Gao,&nbsp;Henan Xin","doi":"10.1002/cdt3.70001","DOIUrl":"https://doi.org/10.1002/cdt3.70001","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Computer-aided detection (CAD) software has been introduced to automatically interpret digital chest X-rays. This study aimed to evaluate the performance of CAD software (JF CXR-1 v3.0, which was developed by a domestic Hi-tech enterprise) in tuberculosis (TB) case finding in China.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>In 2019, we conducted an internal evaluation of the performance of JF CXR-1 v3.0 by reading standard images annotated by a panel of experts. In 2020, using the reading results of chest X-rays by a panel of experts as the reference standard, we conducted an on-site prospective study to evaluate the performance of JF CXR-1 v3.0 and local radiologists in TB case finding in 13 township health centers in Zhongmu County, Henan Province.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Internal assessment results based on 277 standard images showed that JF CXR-1 v3.0 had a sensitivity of 85.94% (95% confidence interval [CI]: 77.42%, 94.45%) and a specificity of 74.65% (95% CI: 68.81%, 80.49%) to distinguish active TB from other imaging conditions. In the on-site evaluation phase, images from 3705 outpatients who underwent chest X-ray detection were read by JF CXR-1 v3.0 and local radiologists in parallel. The imaging diagnosis of local radiologists for active TB had a sensitivity of 32.89% (95% CI: 22.33%, 43.46%) and a specificity of 99.28% (95% CI: 99.01%, 99.56%), while JF CXR-1 v3.0 showed a significantly higher sensitivity of 92.11% (95% CI: 86.04%, 98.17%) (<i>p</i> &lt; 0.05) and maintained high specificity at 94.54% (95% CI: 93.81%, 95.28%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>CAD software could play a positive role in improving the TB case finding capability of township health centers.</p>\u0000 </section>\u0000 </div>","PeriodicalId":32096,"journal":{"name":"Chronic Diseases and Translational Medicine","volume":"11 2","pages":"140-147"},"PeriodicalIF":0.0,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cdt3.70001","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144219992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Alignment of Human Aquaporin 4 and ß-Amyloid Proteins May Indicate Involvement of ß-Amyloid in Brain Water Homeostasis and Prevention of Brain Edema”","authors":"","doi":"10.1002/cdt3.70003","DOIUrl":"https://doi.org/10.1002/cdt3.70003","url":null,"abstract":"<p>S. Lehrer and P. H. Rheinstein, “Alignment of Human Aquaporin 4 and ß-Amyloid Proteins May Indicate Involvement of ß-Amyloid in Brain Water Homeostasis and Prevention of Brain Edema,” <i>Chronic Diseases and Translational Medicine</i> 9 (2023): 177–181. https://doi.org/10.1002/cdt3.64.</p><p>The original article included a Conflict of Interest statement which stated: “The authors declare no conflicts of interest.” The journal and the publisher have determined that a conflict of interest on behalf of each author was not declared at publication. The journal and the publisher have had sufficient communication with the authors via email after raising questions about the Conflict of Interest in the article. The authors declared that there was no undeclared Conflict of Interest and further stated that their individual affiliations with commercial entities did not influence the research findings. Following further correspondence between the publisher and the authors, all parties have agreed to include the following Conflicts of Interest statement with the published article.</p><p>Steven Lehrer serves in a scientific advisory capacity with Fermata Pharma Inc. Peter H. Rheinstein is President of Severn Health Solutions. The scientific content was developed without influence from Fermata Pharma Inc. or Severn Health Solutions.</p>","PeriodicalId":32096,"journal":{"name":"Chronic Diseases and Translational Medicine","volume":"11 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cdt3.70003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145038531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “Alignment of Human KAT2A (GCN5) Histone Acetyltransferase and SARS-CoV-2 Orf8 Viral Proteins”","authors":"","doi":"10.1002/cdt3.70002","DOIUrl":"https://doi.org/10.1002/cdt3.70002","url":null,"abstract":"<p>S. Lehrer and P. H. Rheinstein, “Alignment of Human KAT2A (GCN5) Histone Acetyltransferase and SARS-CoV-2 Orf8 Viral Proteins,” <i>Chronic Diseases and Translational Medicine</i> 9 (2023): 263–265. https://doi.org/10.1002/cdt3.56.</p><p>The original article included a Conflict of Interest statement which stated: “The authors declare no conflicts of interest.” The journal and the publisher have determined that a conflict of interest on behalf of each author was not declared at publication. The journal and the publisher have had sufficient communication with the authors via email after raising questions about the Conflict of Interest in the article. The authors declared that there was no undeclared Conflict of Interest and further stated that their individual affiliations with commercial entities did not influence the research findings. Following further correspondence between the publisher and the authors, all parties have agreed to include the following Conflicts of Interest statement with the published article:</p><p>Steven Lehrer serves in a scientific advisory capacity with Fermata Pharma Inc. Peter H. Rheinstein is President of Severn Health Solutions. The scientific content was developed without influence from Fermata Pharma Inc. or Severn Health Solutions.</p>","PeriodicalId":32096,"journal":{"name":"Chronic Diseases and Translational Medicine","volume":"11 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cdt3.70002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144220359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guide for Authors","authors":"","doi":"10.1002/cdt3.158","DOIUrl":"https://doi.org/10.1002/cdt3.158","url":null,"abstract":"","PeriodicalId":32096,"journal":{"name":"Chronic Diseases and Translational Medicine","volume":"11 1","pages":"81-87"},"PeriodicalIF":0.0,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cdt3.158","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143554612","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development and Initial Use of a New Inflammatory Bowel Disease Clinical Database Integrating Both Eastern and Western Clinical Characteristics","authors":"Jingshuang Yan,&nbsp;Rongrong Ren,&nbsp;Ruqi Chang,&nbsp;Wanyue Dan,&nbsp;Xiaohan Zhang,&nbsp;Fei Pan,&nbsp;Bin Yan,&nbsp;Hongzhe Lee,&nbsp;Ni Josie,&nbsp;Gang Sun,&nbsp;Lihua Peng,&nbsp;Gary D. Wu,&nbsp;Yunsheng Yang","doi":"10.1002/cdt3.70000","DOIUrl":"https://doi.org/10.1002/cdt3.70000","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The increasing incidence of inflammatory bowel disease (IBD) presents significant medical and societal challenges. A well-designed IBD database is crucial for both epidemiological studies and clinical management. However, inconsistencies between regional databases hinder cross-institutional and international research, especially between Eastern and Western societies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We developed a new IBD database, the 301 IBD database, integrating the IBD clinical characteristics from the Penn IBD database (USA) and the latest IBD guidelines and consensus and clinical practices of the Chinese PLA General Hospital (PLAGH). We applied this database to analyze clinical data of IBD inpatients at PLAGH from 2008 to 2023.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The 301 IBD database contains 490 items in 6 sections including demographic characteristics, personal history, clinical phenotype, disease activity, laboratory tests and examinations, and treatment. Features of the 301 IBD database include inpatient focus, biochemical indicators and opportunistic infection focus, and more about ulcerative colitis (UC)-associated complications. Single-center analysis revealed an increasing hospitalization trend, from 2.35% in 2008 to 3.94% in 2023. We found that the clinical characteristics of our UC inpatients are predominantly male (62.5%), extensive lesions (55.1%), low usage of biologics (4.1%), and a high incidence of UC-CRC (3.0%). The clinical characteristics of CD inpatients included male predominance (68.39%), early onset age (35.43 ± 14.75-year-old), and high rate of surgery (25.81%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>The 301 IBD database, integrating Eastern and Western clinical data, provides a valuable tool for IBD clinical research. Future international, multicenter collaborations are expected to further enhance its utility.</p>\u0000 </section>\u0000 </div>","PeriodicalId":32096,"journal":{"name":"Chronic Diseases and Translational Medicine","volume":"11 2","pages":"130-139"},"PeriodicalIF":0.0,"publicationDate":"2025-02-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cdt3.70000","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144220102","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overlap of Takayasu Arteritis and Kawasaki Disease in Infants","authors":"Jingya Li,&nbsp;Yan Sun,&nbsp;Liyuan Xu,&nbsp;Shanshan Li,&nbsp;Ning Ma","doi":"10.1002/cdt3.157","DOIUrl":"https://doi.org/10.1002/cdt3.157","url":null,"abstract":"<p>Echocardiography showed the myocardial ischemia presentation of an 8-month-old boy.\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":32096,"journal":{"name":"Chronic Diseases and Translational Medicine","volume":"11 2","pages":"156-160"},"PeriodicalIF":0.0,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cdt3.157","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144220241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Translational Medicine in Alzheimer's Disease: The Journey of Donanemab From Discovery to Clinical Application","authors":"Nandhini Jayaprakash,&nbsp;Karthikeyan Elumalai","doi":"10.1002/cdt3.155","DOIUrl":"https://doi.org/10.1002/cdt3.155","url":null,"abstract":"<p>Substantial research has been conducted to identify an efficient treatment for Alzheimer's disease (AD). Existing treatments, including cholinesterase inhibitors and N-methyl D-aspartate (NMDA) receptor antagonists, do not reverse or slow the disease course but only treat its manifestations. This limitation has brought attention to the need for treatments that modify the amyloid-beta (Aβ) and tau pathology of the disease. One recent advancement in AD treatment is donanemab, a monoclonal antibody intended to clear Aβ plaques in the brain. It targets pyroglutamyl(3)-Aβ protein (3–42) to remove Aβ deposits and alter the disease course. This review explores the timeline of donanemab use from discovery to clinical use. The pharmacodynamics and pharmacokinetics of the drug are discussed along with typical and suboptimal preclinical and clinical trial results in terms of efficacy, safety, and tolerability. Thus, donanemab is more effective than donepezil and rivastigmine in removing plaques and improving cognition. At the same time, it is not devoid of safety concerns that are typical of the majority of amyloid-targeted medicines. The control to end the treatment after plaque cleaning is a unique selling point for some patients, making it more attractive. The innovation and development of donanemab from research to clinical practice are a clear representation of the role of the field of translational medicine in the practical application of new knowledge in the treatment of AD.</p>","PeriodicalId":32096,"journal":{"name":"Chronic Diseases and Translational Medicine","volume":"11 2","pages":"105-116"},"PeriodicalIF":0.0,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cdt3.155","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144220234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}